Invivyd (NASDAQ:IVVD) Receives Buy Rating from BTIG Research

Invivyd (NASDAQ:IVVD)‘s stock had its “buy” rating reissued by stock analysts at BTIG Research in a note issued to investors on Monday,Benzinga reports. They currently have a $10.00 price objective on the stock.

A number of other analysts have also weighed in on the stock. HC Wainwright reaffirmed a “buy” rating on shares of Invivyd in a research note on Thursday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Invivyd in a research note on Wednesday, April 29th. Finally, Wall Street Zen lowered shares of Invivyd from a “hold” rating to a “strong sell” rating in a research note on Saturday. Three equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average price target of $8.00.

Invivyd Stock Performance

Shares of NASDAQ IVVD opened at $1.21 on Monday. The firm has a market capitalization of $356.48 million, a price-to-earnings ratio of -3.90 and a beta of 0.71. The stock has a 50 day moving average price of $1.52 and a 200 day moving average price of $1.90. Invivyd has a 52-week low of $0.48 and a 52-week high of $3.07.

Invivyd (NASDAQ:IVVD) last announced its quarterly earnings results on Thursday, May 14th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.05). The firm had revenue of $13.74 million during the quarter, compared to analysts’ expectations of $18.04 million. Invivyd had a negative net margin of 138.90% and a negative return on equity of 53.48%. Analysts forecast that Invivyd will post -0.37 earnings per share for the current year.

Insider Buying and Selling at Invivyd

In related news, insider Jill Andersen sold 34,939 shares of the stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $1.58, for a total value of $55,203.62. Following the completion of the transaction, the insider directly owned 181,736 shares of the company’s stock, valued at $287,142.88. This trade represents a 16.13% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO William E. Duke sold 20,964 shares of the stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $1.58, for a total transaction of $33,123.12. Following the completion of the transaction, the chief financial officer directly owned 107,717 shares of the company’s stock, valued at $170,192.86. The trade was a 16.29% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 227,172 shares of company stock valued at $354,534. 12.25% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Invivyd

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Courier Capital LLC purchased a new position in Invivyd in the 4th quarter worth $25,000. Bronte Capital Management Pty Ltd. purchased a new position in Invivyd in the 4th quarter worth $27,000. DRW Securities LLC purchased a new position in Invivyd in the 4th quarter worth $27,000. ProShare Advisors LLC purchased a new position in Invivyd in the 4th quarter worth $30,000. Finally, State of Wyoming purchased a new position in Invivyd during the 4th quarter worth approximately $30,000. Hedge funds and other institutional investors own 70.36% of the company’s stock.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.